

Wells Timberland REIT, Inc.
Form FWP
May 15, 2007

Issuer Free Writing Prospectus
Filed Pursuant to Rule 433(f)
Registration No. 333-129651
May 14, 2007

WELLS TIMBERLAND REIT, INC.

On May 3, 2007, GlobeSt.com, an online financial news publication, published an article concerning Wells Timberland REIT, Inc. (Wells Timberland and, together with its subsidiaries, we , our , and us), the full text of which reproduced below.

Clarifications and Corrections

The article published by GlobeSt.com was not prepared by us or reviewed by us prior to its publication, nor were we aware of the publication of the article prior to May 3, 2007. With the exception of the quotations attributed directly to Mr. Jess E. Jarratt, the article represents the author s opinion which is not endorsed or adopted by us.

We believe that the following information is appropriate to clarify or correct information included in the article:

1. The statement that Mr. Jarratt is the chief timberland officer of Wells Timberland Investment Management Organization, LLC is incorrect. Mr. Jarratt is the president of Wells Timberland Management Organization, LLC (Wells TIMO), Wells Timberland REIT s advisor.

2. With respect to the statement that Wells plans to produce a total return over a seven-to-10-year period in the 10% to 12% range, the article has placed undue emphasis on Wells TIMO s internal target as indicating a plan, which was not stated or intended by Mr. Jarratt. Wells TIMO s internal targeted total returns for Wells Timberland REIT are inherently speculative and uncertain given that our initial public offering is being conducted on a best efforts basis, and to date we have not raised any offering proceeds and have not acquired any assets. As with any forward-looking information, this statement and any other forward-looking statements in the article are subject to risks and uncertainties that could cause the actual results to differ materially from those stated. Please read Cautionary Note regarding Forward-Looking Statements included in the prospectus that we have filed with the SEC in connection with the offering.

3. The statement in the second paragraph of the article that Wells will initially fund the REIT with \$750 million is not endorsed or adopted by us in any manner. Because we have not raised any proceeds in our offering and have not acquired any assets, it would be highly speculative to estimate the net proceeds to be received by us from the sale of shares in our offering which cannot be determined at this time. As disclosed in the prospectus for the offering, we may not be successful in raising any proceeds in the offering.

4. We caution that undue influence should not be placed on the statement in the second paragraph of the article that Jarratt estimates somewhere in the neighborhood of one million acres will be purchased with the initial funding since we have not raised any proceeds in our offering, have not purchased any timberland or other assets and have not identified any timberland for acquisition which we have a reasonable probability of acquiring. As a result, it would be speculative to identify a particular size or acreage of property that we would acquire

with our initial funding since the dollar amount, if any, which we may raise in connection with our offering is speculative and highly uncertain.

GlobeSt.com is a global provider of financial data and news. It is in the business of, among other things, publishing written communications. GlobeSt.com is wholly unaffiliated with Wells Timberland REIT and its affiliates, including Wells TIMO, and neither Wells Timberland REIT nor any of its affiliates made any payment or gave any consideration to GlobeSt.com in connection with the publication of the following article.

Full text of the Globest.com Article

GlobeSt.com

Wells Launches \$750M Timberland REIT

Last updated: May 3, 2007 01:43pm

By Gina Kenny

NORCROSS, GA-Wells Real Estate Funds Inc., based here, is launching a timberland real estate investment trust.

The goal is to provide an investment vehicle for individual investors to invest in timberland that they have never had before, says Jess Jarratt, chief timberland officer and president of Wells Timberland Investment Management Organization. Wells plans to produce a total return over a seven- to 10-year period in the 10% to 12% range, Jarratt tells GlobeSt.com.

Wells will initially fund the REIT with \$750 million. We will use some debt but we will be very conservative, he says. Jarratt estimates somewhere in the neighborhood of one million acres will be purchased with the initial funding. Wells plans for the REIT to have a diverse portfolio with timberland from diverse geographical locations and different age and timber types. There is approximately 500 million acres of commercial timberland in the country with approximately an additional 250 million acres of wild land and other forestland that is not of a commercial nature. Of the commercial timberland, roughly half is owned by private non-industrial individuals, a large chunk is owned by the federal government and industry and institutional investors own the rest, Jarratt says. The REIT has not purchased any timberland yet but We are actively in the market as we speak, Jarratt says. The REIT should be attractive to investors because Timberland's income is typically tax advantaged in that it is capital gain, he says. Wells plans for the REIT to generate revenue through the sale of timber harvesting rights, leasing land-use rights and selling some of the land at a later date. In Southern forests, pulpwood can be sold when timber reaches 15 years, which sells for about \$7 per ton. At about age 22, the timber can be sold for about \$22 per ton for small logs and, at about 29 years, the timber can be sold for larger logs from more than \$40 per ton, Jarratt says. The value proposition for timberland is very simple in that trees grow regardless of what goes on in the marketplace, regardless of interest rates or world events, he says. After the final harvest, Wells plans to replant, making it an ecologically sound, renewable resource, he says.

Wells Timberland REIT, Inc. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents that Wells Timberland REIT, Inc. has filed with the SEC for more complete information about Wells Timberland REIT, Inc. and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, Wells Timberland REIT, Inc., the dealer manager or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free (800) 557-4830.

-2-

ITF Minor Son - DRIP Common Stock	16,658 I	ITF Minor Son - DRIP Common Stock	291,084 I
S.J. Dining Common Stock	309,482 I	U.S. Restaurants Common Stock	02/26/2007 P 240 A \$ 34.31 3,457 I
US Restaurants Deferred Comp. Plan			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Edgar Filing: Wells Timberland REIT, Inc. - Form FWP

Item No.	Caption	Location in Information Statement
1.	Business	Summary , Risk Factors , The Spin-Off , Our Business , Management s Discussion and Analysis of Financial Condition and Results of Operations , Where to Obtain More Information
1A.	Risk Factors	Risk Factors
2.	Financial Information	Historical Selected Financial Data , Unaudited Pro Forma Condensed Combined Balance Sheet , Capitalization , and Management s Discussion and Analysis of Financial Condition and Results of Operations
3.	Properties	Our Business , and Our Relationship with PDL after the Spin-Off ,
4.	Security Ownership of Certain Beneficial Owners and Management	Security Ownership of Certain Beneficial Owners and Management
5.	Directors and Executive Officers	Management , and Board of Directors
6.	Executive Compensation	Compensation Discussion and Analysis
7.	Certain Relationships and Related Transactions and Director Independence	Security Ownership of Certain Beneficial Owners and Management , Related Person Transactions , and Our Relationship with PDL after the Spin-Off , Board of Directors
8.	Legal Proceedings	Our Business
9.	Market Price of Dividends on Registrant s Common Equity and Related Stockholder Matters	The Spin-Off, Dividend Policy , Description of Capital Stock , and Compensation Discussion and Analysis
10.	Recent Sales of Unregistered Securities	Not Applicable
11.	Description of Registrant s Securities to be Registered	The Spin-Off , Dividend Policy and Description of Capital Stock
12.	Indemnification of Directors and Officers	Indemnification of Directors and Officers

Edgar Filing: Wells Timberland REIT, Inc. - Form FWP

Item No.	Caption	Location in Information Statement
13.	Financial Statements and Supplementary Data	Historical Selected Financial Data , and Unaudited Pro Forma Condensed Combined Balance Sheet
14.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	Not Applicable
15.	Financial Statements and Exhibits	See Index to Combined Financial Statements and the statements referenced therein

(a) **Financial Statements**

The information required by this item is contained in the Unaudited Pro Forma Financial Statements and Index to Financial Statements and the statements referenced therein and is incorporated herein by reference.

(b) **Exhibits**

The following documents are filed as exhibits hereto:

Exhibit No.	Exhibit
2.1	Form of Separation and Distribution Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.***
3.1	Amended and Restated Certificate of Incorporation of Facet Biotech Corporation**
3.2	Bylaws of Facet Biotech Corporation**
4.1	Specimen Stock Certificate of Facet Biotech Corporation**
10.1	Form of Transition Services Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.***
10.2	Form of Tax Sharing and Indemnification Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.***
*10.3	2008 Equity Incentive Plan**
*10.4	Form of Notice of Grant of Stock Option under the 2008 Equity Incentive Plan**
*10.5	Form of Stock Option Agreement under the 2008 Equity Incentive Plan**
*10.6	Forms of Notice of Grant of Restricted Stock Award under the 2008 Equity Incentive Plan**
*10.7	Form of Restricted Stock Agreement under the 2008 Equity Incentive Plan**
*10.8	Retention and Severance Plan**
*10.9	Form of Indemnity Agreement**
*10.10	Form of Offer Letter between Facet Biotech Corporation and Faheem Hasnain**

Explanation of Responses:

Edgar Filing: Wells Timberland REIT, Inc. - Form FWP

*10.11 2008 Performance Bonus Program**

10.12 Triple Net Space Lease, effective July 6, 2006, between Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**

Edgar Filing: Wells Timberland REIT, Inc. - Form FWP

- 10.13 Triple Net Space Lease, effective July 6, 2006, between the Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1500 Seaport Boulevard, Redwood City, California)**
- 10.14 Sublease, effective July 6, 2006, between Openwave Systems, Inc. and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**
- 10.15 Collaboration Agreement dated as of September 12, 2005 by and between PDL BioPharma, Inc. and Biogen Idec MA Inc. **
- 10.16 License Agreement dated as of December 15, 2005 by and between Protein Design Labs, Inc. and Human Genome Sciences, Inc. **
- 10.17 Asset Purchase Agreement dated as of February 4, 2008 by and between PDL BioPharma, Inc. and EKR Therapeutics, Inc. **
- 10.18 Clinical Drug Substance Supply Agreement, effective March 13, 2008, between PDL BioPharma, Inc. and GMN, Inc. **
- 10.19 Collaboration Agreement dated as of August 18, 2008 by and between PDL BioPharma, Inc. and Bristol-Myers Squibb Company **
- 21.1 Subsidiaries of Facet Biotech Corporation**
- 99.1 Preliminary Information Statement of Facet Biotech Corporation, dated November 7, 2008

* Management contract or compensatory plan or arrangement.

** Previously filed.

*** To be filed by amendment.

Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant caused this amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Facet Biotech Corporation

Date: November 7, 2008

By:

/s/ Andrew Guggenime
Andrew Guggenime
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.	Exhibit
2.1	Form of Separation and Distribution Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.***
3.1	Amended and Restated Certificate of Incorporation of Facet Biotech Corporation**
3.2	Bylaws of Facet Biotech Corporation**
4.1	Specimen Stock Certificate of Facet Biotech Corporation**
10.1	Form of Transition Services Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.***
10.2	Form of Tax Sharing and Indemnification Agreement by and between Facet Biotech Corporation and PDL BioPharma, Inc.**
*10.3	2008 Equity Incentive Plan**
*10.4	Form of Notice of Grant of Stock Option under the 2008 Equity Incentive Plan**
*10.5	Form of Stock Option Agreement under the 2008 Equity Incentive Plan**
*10.6	Forms of Notice of Grant of Restricted Stock Award under the 2008 Equity Incentive Plan**
*10.7	Form of Restricted Stock Agreement under the 2008 Equity Incentive Plan**
*10.8	Retention and Severance Plan**
*10.9	Form of Indemnity Agreement**
*10.10	Form of Offer Letter between Facet Biotech Corporation and Faheem Hasnain**
*10.11	2008 Performance Bonus Program**
10.12	Triple Net Space Lease, effective July 6, 2006, between Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**
10.13	Triple Net Space Lease, effective July 6, 2006, between the Pacific Shores Investors, LLC and PDL BioPharma, Inc. (for building located at 1500 Seaport Boulevard, Redwood City, California)**
10.14	Sublease, effective July 6, 2006, between Openwave Systems, Inc. and PDL BioPharma, Inc. (for building located at 1400 Seaport Boulevard, Redwood City, California)**
10.15	Collaboration Agreement dated as of September 12, 2005 by and between PDL BioPharma, Inc. and Biogen Idec MA Inc. **
10.16	License Agreement dated as of December 15, 2005 by and between Protein Design Labs, Inc. and Human Genome Sciences, Inc. **
10.17	Asset Purchase Agreement dated as of February 4, 2008 by and between PDL BioPharma, Inc. and EKR Therapeutics, Inc. **
10.18	Clinical Drug Substance Supply Agreement, effective March 13, 2008, between PDL BioPharma, Inc. and GMN, Inc. **

Edgar Filing: Wells Timberland REIT, Inc. - Form FWP

- 10.19 Collaboration Agreement dated as of August 18, 2008 by and between PDL BioPharma, Inc. and Bristol-Myers Squibb Company **
- 21.1 Subsidiaries of Facet Biotech Corporation**
- 99.1 Preliminary Information Statement of Facet Biotech Corporation, dated November 7, 2008

* Management contract or compensatory plan or arrangement.

** Previously filed.

*** To be filed by amendment.

Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.